How much will Mounjaro go up to, and what does that mean for your costs?

The dose range runs from 2.5 mg to 15 mg, and UK private prices follow that range

Most people start Mounjaro at 2.5 mg. That first pen exists to settle your system, not to drive meaningful weight loss; it is a tolerability step. Titration typically happens every four weeks, under prescriber review, moving through 5 mg, 7.5 mg and so on. The majority of patients in clinical trials reached and stayed at higher doses for the treatment to produce its full effect.

In the UK private market, the cost per four-week supply rises with each strength. Eli Lilly raised Mounjaro's UK list price significantly from 1 September 2025: the 15 mg pen's list price moved from around £122 to around £330 per four-week pen, and prices across the range adjusted accordingly. Providers typically price between roughly £149 and £375 per month depending on dose and service. Those figures are widely reported and give a realistic bracket, but the exact figure you pay will depend on which provider you choose and what that price does or does not include. For a clearer picture of how prices are structured across the full range, the Mounjaro price overview sets out what to look for.

The honest implication: if you are wondering how much Mounjaro will cost you across the full course, your monthly outlay at 15 mg will be meaningfully higher than at 2.5 mg, and that is worth planning for before you start, not discovering three months in.

What headline prices often leave out

A common misconception is that the price you see advertised is the price you actually pay. In practice, many providers charge separately for the clinical consultation, the prescription fee, delivery, and any ongoing support. Some charge per pen and add these on at the checkout. Others bundle a dose increase review only if you pay an additional fee. Add those together across a multi-month course and the gap between a low headline price and the real cost can be significant.

There is also the question of what happens when your dose increases. A provider pricing at a lower rate for the starter dose may be operating at a different rate for the maintenance doses you will need long-term. Questions worth asking any provider: is the consultation included, is there a prescription charge, what is the delivery cost, and is clinical support available if something changes mid-course? You can find fuller detail on what the numbers should cover at our Mounjaro pricing breakdown page.

There is also a forward-looking question buried in this keyword. Many patients are asking whether Mounjaro will go up in price again, and that is worth reading separately, the Lilly list-price change in 2025 was a material shift, and some analysts expect further movement as demand for tirzepatide grows. You can also find broader context on whether Mounjaro prices are likely to rise further as part of that picture.

Where nume sits in this, and why we are not the cheapest option

We do not compete on price. That is a deliberate position. At nume, one transparent price covers your consultation, your prescription, your treatment, and free next-working-day delivery. Clinical aftercare is included, and a real prescriber (not software) reviews your case the same day and before every repeat. There are no hidden charges that appear as your dose moves up, and no subscription that locks you in.

You can see exactly what treatment costs at our treatment page, where prices are stated clearly. We do not print per-pen figures here because, frankly, the dose you will need is a clinical determination, not one you should make based on a cost-per-pen comparison before you have spoken to anyone.

The one thing we will say plainly: if cost is the primary filter, we will probably not be the cheapest result you find. A small number of services price below market. That is worth knowing. What it does not tell you is what is included, who is reviewing your prescription, or where the medicine is sourced. The clinical team behind your prescription matters, if you want to know more about ours, our clinical lead's profile is there to read.

Why price is the wrong primary metric for a prescription medicine

The MHRA has issued repeated warnings about counterfeit weight-loss pens sold online without a clinical assessment. Some fake pens have been found to contain insulin. In late 2025, the first illicit UK site producing counterfeit tirzepatide pens was raided. The common thread in every case: the seller was offering these medicines outside any regulated pharmacy structure, at prices that looked competitive. The MHRA's Yellow Card scheme allows you to report suspect sellers, and you can verify any online pharmacy against the GPhC register at GPhC premises number 9012878, that is how you confirm a service is genuinely regulated.

For a prescription medicine taken weekly over months, the question that protects your health is not "what is the cheapest listing?" but "who reviewed my prescription, what did they check, and is this medicine genuine?" NICE's appraisal of tirzepatide (TA1026) sets out the clinical framework that should underpin any responsible prescribing decision. The dose you finish on, and the cost that comes with it, should be the outcome of proper clinical oversight, not a fixed plan you made before a prescriber knew anything about you.

If you have questions before you start, our FAQs cover the most common ones, and our team is reachable through the contact page if you want to speak to someone first.